Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes

Autor:	A. N. Higdon, Shuyu Zhang, Juliana M. Bue-Valleskey, Scott J. Jacober, Edward J. Bastyr, Arun J. Sanyal, Axel Haupt, Annette M. Chang, Mark L. Hartman, Byron J. Hoogwerf, Kenneth Cusi
Rok vydání:	2016
Předmět:	Blood Glucose Male endocrine system diseases Endocrinology Diabetes and Metabolism medicine.medical_treatment Insulin Glargine Type 2 diabetes 030204 cardiovascular system & hematology Gastroenterology Polyethylene Glycols chemistry.chemical_compound 0302 clinical medicine Endocrinology Randomized Controlled Trials as Topic Liver injury Insulin Lispro Fatty liver Alanine Transaminase Liter Middle Aged Magnetic Resonance Imaging Metformin Adipose Tissue Liver Drug Therapy Combination Female medicine.drug Adult medicine.medical_specialty Bilirubin 030209 endocrinology & metabolism 03 medical and health sciences Clinical Trials Phase II as Topic Internal medicine Internal Medicine medicine Humans Hypoglycemic Agents Aspartate Aminotransferases Triglycerides Aged Glycated Hemoglobin Dipeptidyl-Peptidase IV Inhibitors Type 1 diabetes Pioglitazone business.industry Insulin glargine Insulin Cholesterol HDL nutritional and metabolic diseases Cholesterol LDL medicine.disease Hypoglycemia Diabetes Mellitus Type 1 Sulfonylurea Compounds Clinical Trials Phase III as Topic Diabetes Mellitus Type 2 chemistry Thiazolidinediones business
Zdroj:	Diabetes, Obesity and Metabolism. 18:50-58
ISSN:	1462-8902
Popis:	AIMS To compare effects of basal insulin peglispro (BIL), a hepatopreferential insulin, to insulin glargine (glargine) on aminotransferases and liver fat content (LFC) in patients with type 1 and type 2 diabetes (T1D, T2D). MATERIALS AND METHODS Data from two Phase 2 and five Phase 3 randomized trials comparing BIL and glargine in 1709 T1D and 3662 T2D patients were integrated for analysis of liver laboratory tests. LFC, measured by magnetic resonance imaging (MRI) at baseline, 26 and 52 weeks, was analyzed in 182 T1D patients, 176 insulin-naive T2D patients and 163 T2D patients previously treated with basal insulin. RESULTS Alanine aminotransferase (ALT) increased in patients treated with BIL, was higher than in glargine-treated patients at 4-78 weeks (difference at 52 weeks in both T1D and T2D: 7 international units/litre (IU/L), P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91e26f63cf371dadb27ba8e46ea73dc1 https://doi.org/10.1111/dom.12751 Zobrazit plný text záznamu Plný text